4.3 Article

Frequently asked questions on epilepsy, pregnancy and lactation: A EURAP-NL report

期刊

SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
卷 21, 期 8, 页码 606-609

出版社

W B SAUNDERS CO LTD
DOI: 10.1016/j.seizure.2012.06.011

关键词

Antiepileptic drugs; Pregnancy; Frequently asked questions; EURAP

资金

  1. UCB Pharma
  2. Sanofi-Aventis
  3. Janssen-Cilag
  4. GSK
  5. Pfizer
  6. Netherlands Epilepsy Foundation [03-18]

向作者/读者索取更多资源

Purpose: To describe the questions addressed by participants and physicians to the International Registry of Antiepileptic Drugs and Pregnancy centre in the Netherlands (EURAP-NL). Methods: All incoming questions during the study period were systematically inventoried. Characteristics of the inquirer, antiepileptic drugs (AEDs) indicated, question topic, indication for which AEDs were (to be) prescribed, and timing of the question relative to pregnancy were evaluated. Results: Healthcare professionals posed the majority of questions. Lamotrigine, levetiracetam, valproate and carbamazepine were the drugs most frequently referred to. Common reasons to contact EURAP-NL were congenital malformation risks associated with specific AEDs, requests for information updates when available guidelines were considered lacking, and concerns regarding breastfeeding while using AEDs. Conclusions: There is an evident demand for additional information regarding AEDs and pregnancy. Pregnancy registries like EURAP can be a useful tool to identify information deficits and may serve as an information source for the development of guidelines to facilitate common practice among healthcare professionals. (c) 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据